Related Experiment Video
Updated: Jun 9, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Consumers' views of pharmacogenetics--A qualitative study
Catherine A Haddy1, Helena M Ward, Manya T Angley
1School of Pharmacy and Medical Sciences, Sansom Institute, University of South Australia, Frome Road, Adelaide 5000, South Australia.
Research in Social & Administrative Pharmacy : RSAP
|September 4, 2010
Summary
Consumers desire personalized medicine (PGx) but have concerns about side effects, cost, and data privacy. Education for healthcare providers is crucial for successful implementation of pharmacogenetics (PGx).
Area of Science:
- Pharmacogenetics and personalized medicine.
- Public health and adverse drug reactions.
- Consumer perceptions and healthcare implementation.
Background:
- Adverse drug reactions pose a significant public health challenge.
- Pharmacogenetics (PGx) offers potential for personalized medication dosing but is underutilized.
- Limited research exists on consumer perspectives regarding PGx implementation barriers.
Purpose of the Study:
- To explore public views on medication use and side effects.
- To understand consumer opinions on pharmacogenetics (PGx) and its implementation.
- To identify perceived barriers to integrating PGx into clinical practice.
Main Methods:
- Qualitative analysis of 5 focus groups (n=35) with individuals affected by chronic conditions.
- Discussions covered medication experiences and views on PGx, termed "Personalized Medicine".
- Framework approach used for data analysis, with independent coding and thematic comparison.
Main Results:
- Participants expressed a desire for holistic disease management and medication selection.
- Concerns were raised about medication side effects, genetic information privacy, and implementation costs.
- Focus group participants identified potential barriers to pharmacogenetics (PGx) adoption.
Conclusions:
- Pharmacogenetics (PGx) testing is viewed positively if integrated with broader patient factors.
- Effective communication and comprehensive information from healthcare professionals are essential.
- Education for clinicians and pharmacists is vital to meet consumer expectations for PGx implementation.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...